One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
Game Rant on MSN
9 anime where the protagonist actually dies
Some anime have killed their protagonists in unpredictable ways.
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” Q4 2025 investor letter. A copy of the letter can be downloaded here. The Strategy ...
In March, the companies announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC). The study met its ...
Protagonist Therapeutics has shared a closer look at midphase data on its Johnson & Johnson-partnered oral peptide psoriasis drug candidate. The efficacy fell short of the high bar set by injectable ...
Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...
Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results